In the context of streamlining generic approval, this study assessed whether
pharmacokinetics (PK) could elucidate the pulmonary fate of orally inhaled drug products …

This study aimed to gain an in-depth understanding of the pulmonary fate of three
experimental fluticasone propionate (FP) dry powder inhaler formulations which differed in …

The role of plasma pharmacokinetics (PK) for assessing bioequivalence at the target site,
the lung, for orally inhaled drugs remains unclear. A validated semi-mechanistic model …

Background: A novel inhalation-driven multidose dry powder inhaler (MDPI) that eliminates
the need for the patient to coordinate device actuation with inhalation has been developed …

Objective The aim of this analysis was to assess the rate and extent of systemic availability
of inhaled fluticasone propionate (FP) from 2 dry powder systems (Diskhaler® and Diskus®) …

Objective: To evaluate the pharmacokinetic and systemic pharmacodynamic properties of
inhaled fluticasone propionate (FP). Methods: Single doses of 0.25, 0.5, 1.0 and 3.0 mg FP …

Direct comparisons of the pharmacokinetic (PK) and systemic pharmacodynamic (PD)
properties of inhaled corticosteroids after single and multiple dosing in the same subjects …

Objective The aim of these studies was to determine the absolute bioavailability in healthy
volunteers of inhaled fluticasone propionate (FP) administered as a single dose via the …

Background: The use of dry-powder inhalers (DPIs) to administer respiratory medicines is
increasing, and new DPIs are likely to be developed because of expiring patents. However …

Introduction The efficacy of inhaled products is affected by the degree, and potentially the
site, of drug particle deposition in the lungs. Lung deposition correlates with the fine particle …